Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Contineum Therapeutics Inc (CTNM)

Contineum Therapeutics Inc (CTNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry Business Wire - Tue Jun 30, 3:05PM CDT

- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) - Blocking...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference Business Wire - Mon Jun 1, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 14.63 (+0.41%)
MarketBeat.com
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential MarketBeat - Fri May 22, 7:03AM CDT

Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri May 15, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference Business Wire - Tue May 12, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference Business Wire - Mon May 11, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Business Wire - Tue May 5, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri May 1, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain Business Wire - Thu Apr 30, 3:05PM CDT

- The trial achieved its primary endpoint demonstrating favorable safety and tolerability - Encouraging trends observed across multiple exploratory efficacy endpoints...

CTNM : 14.63 (+0.41%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Mar 13, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 14.63 (+0.41%)

Barchart Exclusives

This Dividend Stock Trading Near Multi-Year Lows Is a Risky Buy With Significant Upside Potential Barchart - Wed Jul 15, 6:30PM CDT
FMC stock is trading near the lowest level in over two decades as the company continues to battle several challenges. It, however, can be a speculative buy for aggressive investors given the low valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.